Skip to main content
Fig. 6 | BMC Cancer

Fig. 6

From: A meta-analysis of BRF2 as a prognostic biomarker in invasive breast carcinoma

Fig. 6

MYC and BRF2 alterations co-occur in breast invasive carcinoma and affect overall patient survival. a MYC is amplified in 35.5% of patients with BRF2 alterations, p = 6.638e-6. The breast cancer biomarkers ERBB2 (HER2), ESR1(ER), PIK3CA are not significantly altered in patients with BRF2 alterations. b OncoPrint of BRF2 and MYC alterations in the same data set analyzed in Fig. 7a. BRF2 and MYC are altered in 36% (346 of 960 patients, Breast Cancer Data Set, TCGA, Firehose Legacy) [28, 34, 35]. c BRF2 alterations tend to co-occur with MYC alterations (p = 0.008) and are mutually exclusive with PIK3CA alterations (p = 0.002). d-g Overall survival Kaplan-Meier estimate was determined comparing overall patient survival status, by month, in patients with alterations (red line) to those without alterations (blue line) in PIK3CA (d), BRF2 and PIK3CA (E), MYC (f), BRF2 and MYC (g). Logrank p-value for each overall survival Kaplan-Meier estimated is noted. The Breast Invasive Carcinoma Data set (TCGA, Firehose Legacy) analyzed is available at the cBioPortal (www.cbioportal.org). Queries of the cBioPortal were performed in September 2019, October 2019, November 2019, January 2020, February 2020, and March 2020

Back to article page
\